Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. The Company's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies as well as in-house cell therapy manufacturing. The Company has formed a global strategic collaboration with Roche to unlock the promise of cell therapies for patients with hematological malignancies. Learn more at www.poseida.com.

Astellas Pharma

Boxer Capital

Longitude Capital

Pentwater Capital Management

Perceptive Advisors

Rapha Capital Management

Malin Corporation

Aisling Capital

Schonfeld Strategic Advisors

Fidelity

Fidelity Management and Research Company

Adage Capital Management

Poseida Therapeutics, Inc.

Domain Not Resolving

HSTS

DNSSEC

jQuery CDN

Japanese Yen

Twitter Tweet Button

Mobile Optimized

Drupal

Cloudinary

Adobe Dynamic Tag Management

President, Gene Therapy

Brent Warner

Chief Scientific Officer, Cell Therapy

Devon Shedlock

Consultant

Eric Ostertag

General Counsel, Chief Compliance Officer & Corporate Secretary

Harry Leonhardt

Chief Financial Officer

Johanna Mylet

Executive Chairman

Mark Gergen

Chairman and Chief Executive Officer

Vice President

Blair Madison

Vice President, Head of Statistical and Data Sciences

Hamid Namini

Vice President Procurement

Jennifer Collins

David Hirsch

Mark J. Gergen

President, Chief Business Officer and Director

Kristin Martin

Chief People and Administration Officer

Kristin Yarema

President, Cell Therapy

President and Chief Executive Officer

Syed Rizvi

Chief Medical Officer

Novartis Portfolio Companies

Therapeutics Companies that Exited

Biotechnology Public Companies With More Than $50M in Revenue

Therapeutics Companies (Top 10K)

Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics for patients with high unmet medical needs. The company develops a pipeline of autologous and allogeneic chimeric antigen receptor T cell or CAR-T, product candidates focusing on the treatment of hematological malignancies and solid tumors.

Post-IPO Equity - Poseida Therapeutics

Series D - Poseida Therapeutics

Novartis

Series C - Poseida Therapeutics

California Institute for Regenerative Medicine

Grant - Poseida Therapeutics

Series B - Poseida Therapeutics

Series A - Poseida Therapeutics

San Diego

California

United States

North America

Poseida Therapeutics

Poseida Therapeutics offers preclinical highlights of CAR T pipeline

Poseida Therapeutics holds virtual R&D Day

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

Poseida Therapeutics GAAP EPS of $0.21, revenue of $71.7M (PSTX:NASDAQ)

Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

Poseida Therapeutics reports data from Phase 1 trial of P-BCMA-ALLO1

Poseida Therapeutics to Present at Upcoming Investor Conferences

Poseida Therapeutics files for mixed shelf offering of up to $300M (NASDAQ:PSTX)

A non-viral system for inserting large genetic payloads into the genome.

A technology for making accurate site-specific deletions, insertions, and knock-ins in multiple cell types.

Off-the-shelf CAR-T products focusing on specific cell populations for cancer treatment.

Developing functional cures for rare genetic diseases by targeting specific cell types.

An off-the-shelf CAR-T treatment in development for epithelial-derived solid tumors.

An allogeneic CAR-T treatment in development for relapsed/refractory multiple myeloma.

India

Asia

Philippines

France

Europe

Pakistan

HTML5

Microsoft Outlook

Google Tag Manager

Google Fonts

Modernizr

Google Compute Engine

Adobe Fonts

F5 NGINX

DigiCert

Apache Server

Regenxbio Inc is a biotechnology company that focuses on the development, commercialization, and licensing of gene therapy treatments.

Regenxbio Inc

TCR2 Therapeutics is a clinical-stage immunotherapy company that develops novel T cell therapies for patients suffering from cancer.

TCR2 Therapeutics

DiaCarta is a molecular diagnostics company that specializes in the development and commercialization of innovative blood-based tests for cancer detection and monitoring.

DiaCarta

Mission Bio is a life sciences company that develops and commercializes single-cell DNA analysis solutions for cancer research and precision medicine applications.

Mission Bio

Quadrants Scientific is a company that provides innovative scientific and laboratory solutions, including products and services for the biotechnology and pharmaceutical industries.

Quadrants Scientific

Poseida Therapeutics is a clinical-stage biopharmaceutical company focused on developing groundbreaking cell and gene therapies for patients with high unmet medical needs. The company's genetic engineering technologies aim to redefine treatment paradigms for life-threatening cancers and genetic diseases.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

news impact assignment basic	general	Feb 16, 2024 12:50 AM	af64a3f7
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 16, 2024 12:50 AM	d0e89c3e
company summary	general
signals	general
crunchbase trigger	general	Nov 18, 2024 2:12 PM	098f1ac4
crunchbase profile	general	Nov 19, 2024 11:27 AM	c262ed17
li profile	general	Feb 16, 2024 12:50 AM	b9500b6a
translate crunchbase fundingrounds	general	Nov 19, 2024 1:15 PM	f423d0c5
peers	general	Feb 16, 2024 12:50 AM	35da72e5
news basic	general	Feb 16, 2024 12:50 AM	953ad404
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:POSEIDA

Poseida Therapeutics, Inc.

Last Close

2.72

21/11 21:00

Market Cap

288.93M

Beta: -

Volume Today

296.17K

Avg: -